Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González‐Duarte et al.|The Lancet Neurology|2020Cited by 160
Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension PeriodRebecca R. Hung, Matthew J. Maurer, Julian D. Gillmore et al.|Circulation|2023Cited by 6
RED CELL DISTRIBUTION WIDTH IN HEART FAILURE: A MULTIMARKER OF DIFFERENT PATHOPHYSIOLOGICAL PATHWAYSNicolas Thibodeau-Jarry, Ellen S. O’Meara, Anique Ducharme et al.|Canadian Journal of Cardiology|2014Cited by 0